<DOC>
	<DOCNO>NCT00502853</DOCNO>
	<brief_summary>This single arm study measure effect MabThera combination methotrexate progression synovitis , extent bone marrow edema , number erosion wrist hand patient rheumatoid arthritis , use new MRI technique . Patients receive MabThera 1000mg i.v . day 1 15 , combination stable dosage 10-25mg/week methotrexate throughout duration study . Further course MabThera provide eligible patient . MRI perform 1-2 week treatment initiation , repeat 1 6 month first MabThera infusion . The anticipated time study treatment 1-2 year , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Pilot Study MabThera ( Rituximab ) Evaluated MRI Patients With Rheumatoid Arthritis .</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>adult patient , 1875 year age ; rheumatoid arthritis &gt; =3 month &lt; =10 year ; inadequate response methotrexate ( 12.525mg/week ) &gt; =3 month ; evidence erosive disease and/or clinical synovitis signal joint . autoimmune rheumatic disease RA ; surgical operation bones/joints 12 week prior baseline visit ; concomitant treatment biologic agent ; previous treatment one biologic agent approve RA , celldepleting therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>